GW&K Investment Management’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $77M | Buy |
|
|||||
|
2025
Q1 | $56.6M | Sell |
|
|||||
|
2024
Q4 | $70.2M | Buy |
|
|||||
|
2024
Q3 | $58.8M | Sell |
|
|||||
|
2024
Q2 | $75.2M | Buy |
|
|||||
|
2024
Q1 | $72.8M | Sell |
|
|||||
|
2023
Q4 | $70.6M | Sell |
|
|||||
|
2023
Q3 | $62.4M | Sell |
|
|||||
|
2023
Q2 | $54.1M | Sell |
|
|||||
|
2023
Q1 | $58.8M | Buy |
|
|||||
|
2022
Q4 | $68.6M | Sell |
|
|||||
|
2022
Q3 | $63.2M | Sell |
|
|||||
|
2022
Q2 | $60.1M | Sell |
|
|||||
|
2022
Q1 | $63.7M | Buy |
|
|||||
|
2021
Q4 | $39.1M | Buy |
|
|||||
|
2021
Q3 | $42.6M | Sell |
|
|||||
|
2021
Q2 | $43.7M | Buy |
|
|||||
|
2021
Q1 | $42.9M | Buy |
|
|||||
|
2020
Q4 | $37.1M | Sell |
|
|||||
|
2020
Q3 | $37.4M | Buy |
|
|||||
|
2020
Q2 | $46M | Buy |
|
|||||
|
2020
Q1 | $32.3M | Buy |
|
|||||
|
2019
Q4 | $31.1M | Sell |
|
|||||
|
2019
Q3 | $26.8M | Buy |
|
|||||
|
2019
Q2 | $19.9M | Sell |
|
|||||
|
2019
Q1 | $21M | Buy |
|
|||||
|
2018
Q4 | $16.6M | Buy |
|
|||||
|
2018
Q3 | – | Sell |
|
|||||
|
2018
Q2 | $8.07M | Sell |
|
|||||
|
2018
Q1 | $6.84M | Sell |
|
|||||
|
2017
Q4 | $7.1M | Buy |
|
|||||
|
2017
Q3 | $5.01M | Sell |
|
|||||
|
2017
Q2 | $3.81M | Sell |
|
|||||
|
2017
Q1 | $3.67M | Sell |
|
|||||
|
2016
Q4 | $3.34M | Buy |
|
|||||
|
2016
Q3 | $4.06M | Sell |
|
|||||
|
2016
Q2 | $3.89M | Buy |
|
|||||
|
2016
Q1 | $2.65M | Buy |
|